InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

Shares of InspireMD stock opened at $2.69 on Wednesday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85. The firm has a market capitalization of $67.06 million, a P/E ratio of -3.54 and a beta of 0.91. The company’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $2.54.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The company had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the prior year, the business earned ($0.24) EPS. On average, analysts expect that InspireMD will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently raised its position in InspireMD stock. Rosalind Advisors Inc. raised its stake in InspireMD, Inc. (NYSE:NSPR) by 266.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,513,641 shares of the company’s stock after purchasing an additional 1,827,579 shares during the period. InspireMD accounts for 4.6% of Rosalind Advisors Inc.’s holdings, making the stock its 8th biggest holding. Rosalind Advisors Inc. owned 10.08% of InspireMD worth $6,272,000 as of its most recent filing with the Securities and Exchange Commission. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.